Evidence map›Paper›PMID 42339130›Full record

ArticleFrontiers in bioinformatics2026

Harnessing cutting-edge techniques to identify novel gene expression signatures in acute myeloid leukemia patients.

Adriana Blanda, Rebecca Manitto, Sara Pizzamiglio, Sabina Sangaletti, Paolo Verderio

Abstract read
In one paragraph

Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adriana Blanda *Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Rebecca Manitto *Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Sara PizzamiglioUnit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Sabina Sangaletti *Unit of Molecular Immunology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Paolo Verderio *Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Acute Myeloid Leukemia (AML) is a heterogeneous hematological malignancy with poor prognosis, despite therapeutic advances. Gene expression analysis has emerged as a powerful tool for identifying novel biological markers that can aid in predicting patient outcomes. This study is aimed to identify prognostic gene expression signatures from RNA-seq data of 457 AML patients. Methods: Filtering methods were applied to reduce the set of genes, resulting in a subset of 685. Lasso-Cox, Bayesian Model Averaging (BMA), Random Survival Forest (RSF), and a Cox-time Neural Network (CtNN) were implemented to select the most promising prognostic genes. Explainable tools such as SHapley Additive exPlanations (SHAP) and Local Interpretable Model-agnostic Explanations (LIME) were used to gain a deeper understanding of neural network outputs. An enrichment analysis was performed to identify enriched biological pathways. Results: SHAP and LIME interpretations of the CtNN output identified gene sets that differed from those selected by the other algorithms. According to the two-validation metrics the SHAP-derived signature demonstrated superior performance in the testing set. (C-index[95%CI]: 0.639[0.581-0.696] and Integrated Brier Score [95%CI]: 0.172[0.161-0.183]). Discussion: Enrichment analysis revealed structural and developmental pathways, emphasizing the role of microtubule dynamics and ciliary-related signaling in the bone marrow microenvironment.

Indexed as

acute myeloid leukemiacross-validationmachine learningperformance metricssurvival analysis

Identifiers

PMID42339130
PMCPMC13284140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.